Slingshot members are tracking this event:
Aimmune (AIMT) to Complete Up-dosing of Peanut Allergy Patients Taking AR101 in Phase 3 PALISADE Trial in H1 2017
Slingshot Insights Explained
Mar 06, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Up-dosing, Peanut Allergies, Ar101, Phase 3 Palisade Trial